|
|
5-day change | 1st Jan Change | ||
|
0.0690 AUD |
+6.15% | +6.15% | -13.75% | |
Published on 06/09/2025 at 22:31
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Syntara Receives US FDA Fast Track Designation for Myelofibrosis Treatment Candidate; Shares Jump 4% |
10:31pm |
MT |
|
Syntara Says SNT-5505 Awarded U.S. FDA Fast Track Designation |
07:05pm |
RE |
|
Commercial, Development-Stage Biotechs Expected to See Little Impact from US Drug Pricing Order, Euroz Hartleys Says |
May. 14 |
MT |
|
Syntara Has Estimated AU$3.6 Billion Market Opportunity for Its Cancer Drug Candidate, Says Euroz Hartleys |
May. 05 |
MT |
|
Syntara Limited, Q3 2025 Earnings Call, May 01, 2025 |
Apr. 30 |
|
|
Syntara’s Valuation Assumes $750 Million Licensing Deal for Drug Candidate, Eruoz Hartleys Says |
Mar. 27 |
MT |
|
Syntara Develops Drug Candidate for Hypertrophic Scars, Shares Rise 3% |
Mar. 18 |
MT |
|
Syntara Limited – Special Call |
Mar. 17 |
|
|
Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2024 |
Feb. 25 |
CI |
|
Syntara Limited – Shareholder/Analyst Call |
Feb. 16 |
|
|
Syntara Limited Announces Board Changes |
Feb. 06 |
CI |
|
Syntara Limited Announces Positive Interim Data in Phase 2 Study of SNT-5505 in Myelofibrosis |
Dec. 10 |
CI |
|
Syntara Limited – Special Call |
Dec. 09 |
|
|
Syntara Limited – Shareholder/Analyst Call |
Nov. 27 |
|
|
Syntara Limited, Q1 2025 Earnings Call, Oct 30, 2024 |
24-10-29 |
|
|
Syntara Limited – Shareholder/Analyst Call |
24-09-19 |
|
|
Syntara Limited Auditor Raises ‘Going Concern’ Doubt |
24-08-29 |
CI |
|
Syntara Grants CEO Performance Rights Under Incentive Scheme |
24-08-15 |
MT |
|
Syntara Appoints CFO |
24-08-15 |
MT |
|
Syntara Limited Announces CFO Changes |
24-08-15 |
CI |
|
Syntara Secures AU$2.5 Million Grant Funding for Blood Cancer Trial |
24-08-07 |
MT |
|
Syntara Completes Patient Recruitment for Phase-Two Bone Marrow Cancer Treatment Trial |
24-07-31 |
MT |
|
Syntara Raises About AU$5 Million for Clinical Trials, Studies; Shares Fall 25% |
24-07-30 |
MT |
|
Syntara Limited Reports Earnings Results for the Fourth Quarter Ended June 30, 2024 |
24-07-29 |
CI |
|
Syntara Limited Presents at MST Access ‘Hidden Gems in Life Sciences’ Webinar, Jun-13-2024 02:30 PM |
24-06-13 |
SNT: Dynamic Chart
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
More about the company
Buy
Last Close Price
0.0690AUD
Average target price
0.1900AUD
Spread / Average Target
+175.36%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
